^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IMPDH inhibitor

    Related drugs:
    19h
    PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=82, Completed, Duke University | N=167 --> 82
    Enrollment change • HEOR
    7d
    Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME) (clinicaltrials.gov)
    P3, N=88, Completed, Centre Hospitalier Universitaire, Amiens | Unknown status --> Completed
    Trial completion
    |
    everolimus • cyclosporin A microemulsion
    10d
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    11d
    Islet Transplantation With Recipient T-Reg Cells or Deceased Donor Vertebral Bone Marrow Therapy (clinicaltrials.gov)
    P1, N=24, Enrolling by invitation, Stanford University | Trial completion date: May 2028 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2030 | Not yet recruiting --> Enrolling by invitation
    Enrollment open • Trial completion date • Trial primary completion date
    11d
    Immunopathogenesis of Mayaro Virus-Induced Chronic Arthritis: From Inflammatory Pathways to Targeted Therapeutic Strategies. (PubMed, Vector Borne Zoonotic Dis)
    The article provides a critical evaluation of current and developing therapeutic strategies, including antiviral agents such as favipiravir and immunomodulatory agents targeting IL-1β, tumor necrosis factor, and IL-6 signaling. Understanding the interplay between viral determinants and host immune responses is critical for the rational design of effective interventions against MAYV-induced chronic inflammation and arthritis.
    Review • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    16d
    MYCOHYPE: An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis (clinicaltrials.gov)
    P4, N=144, Active, not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    prednisolone
    16d
    A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sound Pharmaceuticals, Incorporated | Phase classification: P2b --> P2 | N=180 --> 0 | Trial completion date: Oct 2021 --> Jun 2026 | Unknown status --> Withdrawn | Trial primary completion date: Jun 2021 --> Jun 2026
    Phase classification • Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    16d
    AGORAC: Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure (clinicaltrials.gov)
    P3, N=300, Recruiting, Nantes University Hospital | Trial completion date: Oct 2026 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    16d
    SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sound Pharmaceuticals, Incorporated | N=80 --> 0 | Trial completion date: Sep 2019 --> Jun 2026 | Unknown status --> Withdrawn | Trial primary completion date: Jun 2019 --> Jun 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    17d
    Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma. (PubMed, Cureus)
    A diagnosis of statin-associated anti-HMGCR IMNM was established, and treatment with mycophenolate mofetil and intravenous immunoglobulin resulted in partial biochemical improvement...Further evaluation revealed mantle cell lymphoma with bone marrow involvement, IGH::CCND1 rearrangement, and TP53 deletion, consistent with high-risk disease. In this context, continued clinical and laboratory monitoring is appropriate in inflammatory myopathy, and new hematologic abnormalities warrant further evaluation.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1)
    |
    TP53 deletion
    20d
    Vesicular QSOX1-MMP2 from inflammatory cancer-associated fibroblasts degrades the extracellular matrix to drive colorectal cancer pulmonary dissemination. (PubMed, Cancer Lett)
    Notably, Ebselen enhanced the anti-metastatic efficacy of anti-PD-L1 therapy to further suppress CRPM without augmenting toxicity. Our results establish EV-associated QSOX1-MMP2 as a pivotal regulator of metastatic niche remodeling and propose QSOX1 targeting, either alone or in combination with immune checkpoint blockade, as a promising therapeutic approach for CRPM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MMP2 (Matrix metallopeptidase 2) • TGFB1 (Transforming Growth Factor Beta 1) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    23d
    TAOIST: TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Hospices Civils de Lyon | N=300 --> 600
    Enrollment change
    |
    KEAP1 (Kelch Like ECH Associated Protein 1)